ACTELION ANNOUNCES BUILD PROGRAM RESULTS

A A

Actelion has announced that in the BUILD program with bosentan (Tracleer) in patients suffering from either idiopathic pulmonary fibrosis (IPF) or pulmonary fibrosis related to systemic sclerosis, no effect was shown on the primary endpoint of exercise improvement as measured by the six-minute-walk test.

In the IPF study, although not statistically significant, positive trends were observed for pre-defined secondary endpoints, such as the combined incidence of death or treatment failure at 12 months, representing a relative risk reduction of 38 percent.

In both studies, the use of bosentan was well-tolerated. The observed safety profile was consistent with earlier findings in clinical studies that led to the approval of Tracleer in pulmonary arterial hypertension.